Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.51 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284856 | 0.91 | MTNR1A (0.62) | MTNR1ATDP1MEN1KMT2AMPO | |
| SCHEMBL7340131 | 0.85 | TDP1 (0.58) | MTNR1ATDP1GPR84CDYLACP3 | |
| SCHEMBL4564283 | 0.84 | MTNR1A (0.54) | MTNR1ATDP1GPR84CDYLMEN1 | |
| SCHEMBL1566760 | 0.83 | TDP1 (0.56) | MTNR1ATDP1GPR84CDYLACP3 | |
| SCHEMBL3630056 | 0.83 | MTNR1A (0.56) | MTNR1ATDP1GPR84CDYLMEN1 | |
| SCHEMBL1218835 | 0.83 | TDP1 (0.67) | MTNR1ATDP1GPR84CDYLMEN1 | |
| SCHEMBL30307853 | 0.83 | TDP1 (0.67) | MTNR1ATDP1GPR84CDYLMEN1 | |
| SCHEMBL9321175 | 0.82 | MTNR1A (0.47) | MTNR1AMPOKDM4E | |
| SCHEMBL2300013 | 0.81 | TDP1 (0.55) | MTNR1ATDP1GPR84CDYLACP3 | |
| Hydrochloric Acid SCHEMBL11319694 | 0.81 | TDP1 (0.65) | MTNR1ATDP1GPR84CDYLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1353609-B | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO | 2011-07-13 | — | — | CN | claimed |
| EP-1814860-B1 | SUBSTITUTED 5-CARBOXYAMIDE PYRAZOLES AND [1,2,4]TRIAZOLES AS ANTIVIRAL AGENTS | SCHERING CORP (US) | 2009-06-03 | — | — | EP | claimed |
| EP-1708992-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | claimed |
| EP-1624868-A1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS | Pfizer Limited (GB) | 2006-02-15 | — | — | EP | claimed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | claimed |
| WO-2004100950-A1 | ‘(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)-PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-25 | — | — | WO | claimed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | claimed |
| CN-1353609-A | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2002-06-12 | — | — | CN | claimed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | claimed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | claimed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | claimed |
| CN-114671900-B | Boric acid compound and application thereof | 广州医科大学 | 2025-01-28 | — | — | CN | disclosed |
| CN-107690436-B | Method for forming complexes, complexes and use thereof | 庄信万丰股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| US-5162553-A | Processes for preparing optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compounds and intermediates therefor | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| US-5066816-A | PROCESSES FOR PREPARING OPTICALLY ACTIVE 3,4-DIHYDRO-3,4-EPOXY-2H-1-BENZOPYRAN COMPOUNDS AND INTERMEDIATES THEREFOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1991-11-19 | — | — | US | disclosed |
| EP-0456266-A1 | Method for preparing optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compounds, intermediates therefor and uses thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1991-11-13 | — | — | EP | disclosed |
| EP-0386640-A2 | Processes for preparing optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compounds and intermediates therefor | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | MTNR1A 3451/4885TDP1 232/4885GPR84 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.